Chesnara To Buy HSBC Life UK From HSBC Bank In GBP 260 Mln Deal

Chesnara plc (CSN.L) announced its largest acquisition to date, agreeing to purchase HSBC Life (UK) Limited from HSBC Bank plc for £260 million in cash. This strategic move, contingent on regulatory approvals and expected to close in early 2026, will significantly expand Chesnara's scale, adding approximately £4 billion in assets under administration and 454,000 policies, bringing the combined group's AuA to around £18 billion. The acquisition will be funded through existing cash, a £65 million revolving credit facility drawdown, and a £140 million fully underwritten rights issue at 176p per share. Chesnara projects over £800 million in incremental lifetime cash generation from the acquired entity, anticipates a 6% increase in its final FY25 and interim FY26 dividends, and expects potential inclusion in the FTSE 250 index, highlighting the transaction's accretive nature and material step-up for the consolidator.

Analysis

Chesnara plc is executing its largest acquisition to date, a strategically significant transaction to acquire HSBC Life (UK) for £260 million in cash. This move will materially increase Chesnara's scale, adding approximately £4 billion in assets under administration (AuA) and 454,000 policies, bringing the combined group's AuA to around £18 billion. Management has presented the deal as highly accretive, projecting over £800 million in incremental lifetime cash generation, with £140 million expected in the first five years post-completion. The financing structure is diversified, utilizing £55 million in existing cash, a £65 million drawdown from an upsized credit facility, and a substantial, fully underwritten £140 million rights issue at 176p per share. A key signal of confidence is the company's guidance for a 6% adjusted increase to its final FY25 and interim FY26 dividends, extending its 20-year history of dividend growth. The potential for future inclusion in the FTSE 250 index could further enhance the company's market profile, though the transaction's completion remains subject to regulatory approval with a target date in early 2026.

Key Decisions for Investors

• Investors should view this as a transformative, accretive acquisition for Chesnara that is expected to significantly boost long-term cash generation and directly supports a 6% dividend increase, reinforcing the stock's appeal for income-focused portfolios.
• Existing shareholders must evaluate the £140 million rights issue at 176p, as participation is necessary to avoid dilution from the significant equity raise required to fund the transaction.
• The long closing timeline to early 2026 introduces a period of execution and regulatory risk that must be monitored, as any delays or adverse rulings could impact the projected financial benefits.
• For investors in HSBC, this deal represents a minor, non-core asset disposal consistent with strategic simplification and is not expected to be a material event for the banking group.